Novartis's SWOT analysis: pharma giant faces generic threats, eyes new growth

Novartis (NVS) faces upcoming generic competition for key drugs like Entresto in 2025, but projects mid- to high-single digit sales growth and high-single to low-double digit core operating income growth, exceeding analyst expectations. The company's optimism is fueled by strong performance from drugs like Leqvio, expected to reach blockbuster status, and a focus on its pipeline, particularly Pelacarsen, a cardiovascular treatment with Phase 3 results expected in 2026. While generic erosion poses a risk to revenue and margins, Novartis aims to offset this through operational efficiency and strategic investments in high-growth areas, with analysts revising EPS estimates upward for 2025.

Analysis

Novartis AG (NVS), with a market capitalization of $221.27 billion, presents a mixed outlook characterized by robust near-term financial guidance and significant long-term challenges from generic competition. The company projects mid- to high-single digit net sales growth and high-single to low-double digit core operating income growth for 2025, surpassing consensus expectations. This optimism is underpinned by an 11.5% revenue growth, a strong gross profit margin of 75.68%, and an InvestingPro financial health score of 3.17 ("GREAT"). Consequently, analysts have revised 2025 EPS estimates upward to $8.86 from $8.20, with 2026 EPS at $8.71. Revenue is projected at $53,825 million for 2025, with a slight decrease to $54,113 million in 2026 anticipated due to generic erosion of key products like Entresto, Promacta, and Tasigna, expected to launch in 2025. Novartis aims to mitigate this impact through operational efficiency, with SG&A expenses guided to grow below sales. Leqvio, an LDL-cholesterol lowering treatment, is a key growth driver, on track for blockbuster status ($1 billion+ sales) in 2025, capitalizing on a largely untapped secondary prevention market where only 2% of U.S. patients receive advanced treatments. However, the company's future growth heavily relies on its pipeline, particularly Pelacarsen, a cardiovascular treatment targeting Lp(a), with pivotal HORIZON Phase 3 trial data now expected in the first half of 2026, a delay introducing uncertainty. Novartis maintains a return on invested capital of 23%, a P/E ratio of 17.53, and offers a 2.3% dividend yield. While InvestingPro suggests the stock is undervalued, the success of Pelacarsen and the ability to offset generic pressures are critical determinants for its future trajectory, with long-term pipeline concerns beyond 2027 for other brands also noted.

Key Decisions for Investors

• Investors should weigh Novartis's strong 2025 guidance and current product momentum, such as Leqvio's growth, against the significant revenue headwinds from impending generic competition for major drugs starting in 2025.
• Closely monitor the sales trajectory of Leqvio and critically, the clinical trial results for Pelacarsen, expected in H1 2026, as these are key catalysts for offsetting generic impact and driving future growth.
• Consider the company's valuation (P/E 17.53, ROIC 23%) and InvestingPro's undervaluation assessment in the context of the binary risk associated with pipeline success versus patent cliff pressures.
• Evaluate Novartis's ability to manage SG&A expenses effectively and execute on new product launches to bridge the revenue gap created by generic erosion.
• For those with a longer-term horizon, assess the sustained innovation and development beyond Pelacarsen, particularly addressing concerns for the pipeline post-2027.